E-cadherin Expression is Associated with Susceptibility and Clinicopathological Characteristics of Thyroid Cancer: A PRISMA-compliant Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2019 Jul 27

PMID 31348230

Citations 11

Authors

Changlin Zhou

Chunsheng Yang

Daoqun Chong

Affiliations

Soon will be listed here.

Abstract

Background: Recently, many studies have been carried out to investigate the clinicopathological significance of E-cadherin expression in thyroid cancer. However, the results remained inconsistent. In the present study, we performed a meta-analysis to evaluate the associations of E-cadherin expression with susceptibility and clinicopathological characteristics of thyroid cancer.

Methods: Eligible studies were searched from Medicine, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases. The strength of associations between E-cadherin expression and susceptibility and clinicopathological features of thyroid cancer were assessed by pooled odds ratios (ORs) and 95% confidence intervals (CIs).

Results: Forty-six studies with 1700 controls and 2298 thyroid cancer patients were included for this meta-analysis. Pooled results indicated that E-cadherin expression was significantly associated with susceptibility of papillary cancer and follicular cancer (papillary cancer, ORs = 14.31, 95% CIs = 3.42-59.90; follicular cancer, ORs = 10.14, 95% CI = 4.52-22.75). Significant association between E-cadherin expression and thyroid cancer risk was also observed in the subgroup analysis based on control group (normal thyroid tissue, ORs = 28.28, 95% CI = 8.36-95.63; adjacent thyroid tissue, ORs = 8.83, 95% CI = 3.27-23.85; benign thyroid tissue, ORs = 43.96, 95% CI = 9.91-194.95). In addition, E-cadherin expression was significantly correlated with lymph node metastasis, differentiation, and tumor-node-metastasis (TNM) stage of thyroid cancer (lymph node metastasis, ORs = 3.21, 95% CI = 1.98-5.20; differentiation, ORs = 0.25, 95% CI = 0.07-0.82; TNM stage, ORs = 4.85, 95% CI = 2.86-8.25).

Conclusions: The present study showed that E-cadherin expression was significantly associated with susceptibility and clinicopathological characteristics of thyroid cancer, which suggested that E-cadherin expression might be a potential predictive factor for clinical progression of thyroid cancer.

Citing Articles

Dexamethasone Selectively Inhibits Detachment of Metastatic Thyroid Cancer Cells during Random Positioning.

Melnik D, Cortes-Sanchez J, Sandt V, Kahlert S, Kopp S, Grimm D Cancers (Basel). 2023; 15(6).

PMID: 36980530 PMC: 10046141. DOI: 10.3390/cancers15061641.

The Correlation between Proliferative Immunohistochemical Markers and Papillary Thyroid Carcinoma Aggressiveness.

Sheikh-Ahmad M, Shalata Y, Bejar J, Kreizman Shefer H, Sirhan M, Laniado M Medicina (Kaunas). 2023; 59(1).

PMID: 36676734 PMC: 9862399. DOI: 10.3390/medicina59010110.

[Influence of E-cadherin methylation on prognosis in children with acute lymphoblastic leukemia].

Qi F, Han W, Yan J, Xin C, Li Y, Guo L Zhongguo Dang Dai Er Ke Za Zhi. 2023; 25(1):46-50.

PMID: 36655663 PMC: 9893830. DOI: 10.7499/j.issn.1008-8830.2208018.

Aberrant NSG1 Expression Promotes Esophageal Squamous Cell Carcinoma Cell EMT by the Activation of ERK Signaling Pathway.

Lin X, Tu M, Zhang Y, Zhuang W, Cai L, Zhang L Dig Dis Sci. 2022; 68(5):1847-1857.

PMID: 36396779 DOI: 10.1007/s10620-022-07748-6.

Circulating microRNAs and Clinicopathological Findings of Papillary Thyroid Cancer: A Systematic Review.

Geropoulos G, Psarras K, Papaioannou M, Giannis D, Meitanidou M, Kapriniotis K In Vivo. 2022; 36(4):1551-1569.

PMID: 35738604 PMC: 9301440. DOI: 10.21873/invivo.12866.

References

Naxerova K, Reiter J, Brachtel E, Lennerz J, van de Wetering M, Rowan A . Origins of lymphatic and distant metastases in human colorectal cancer. Science. 2017; 357(6346):55-60. PMC: 5536201. DOI: 10.1126/science.aai8515. View

Alvarez-Nunez F, Bussaglia E, Mauricio D, Ybarra J, Vilar M, Lerma E . PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid. 2006; 16(1):17-23. DOI: 10.1089/thy.2006.16.17. View

Horne H, Sherman M, Garcia-Closas M, Pharoah P, Blows F, Yang X . Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression. Breast Cancer Res Treat. 2013; 143(1):181-7. PMC: 4159747. DOI: 10.1007/s10549-013-2771-z. View

Luo M, Li Z, Wang W, Zeng Y, Liu Z, Qiu J . Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer Lett. 2013; 333(2):213-21. DOI: 10.1016/j.canlet.2013.01.033. View

Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View

Kapran Y, Ozbey N, Molvalilar S, Sencer E, Dizdaroglu F, Ozarmagan S . Immunohistochemical detection of E-cadherin, alpha- and beta-catenins in papillary thyroid carcinoma. J Endocrinol Invest. 2002; 25(7):578-85. DOI: 10.1007/BF03345079. View

Murugan A, Dong J, Xie J, Xing M . Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers. Endocr Pathol. 2011; 22(2):97-102. PMC: 3133631. DOI: 10.1007/s12022-011-9155-x. View

Liu Y, Jiang C, Tan Y . [Pathological study on the expression of cell adhesion molecules and metastasis suppressor gene in thyroid follicular carcinoma and papillary carcinoma]. Zhonghua Bing Li Xue Za Zhi. 2002; 31(4):322-6. View

Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, Ibrahim M . Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab. 2007; 93(2):611-8. DOI: 10.1210/jc.2007-1717. View

10.

Tsiambas E, Ragos V, Georgakopoulos G, Rigopoulos D, P Fotiades P, Chatziioannidis A . E-cadherin/α-catenin deregulated co-expression in thyroid carcinoma based on tissue microarray digital image analysis. J BUON. 2016; 21(2):450-5. View

11.

Parmar M, Torri V, Stewart L . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1999; 17(24):2815-34. DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8. View

12.

Nakamura M, Onoda N, Noda S, Kashiwagi S, Aomatsu N, Kurata K . E-cadherin expression and cell proliferation in the primary tumor and metastatic lymph nodes of papillary thyroid microcarcinoma. Mol Clin Oncol. 2014; 2(2):226-232. PMC: 3917781. DOI: 10.3892/mco.2013.220. View

13.

Ozolins A, Narbuts Z, Strumfa I, Volanska G, Gardovskis J . Diagnostic utility of immunohistochemical panel in various thyroid pathologies. Langenbecks Arch Surg. 2010; 395(7):885-91. DOI: 10.1007/s00423-010-0690-6. View

14.

Bae W, Hennighausen L . Canonical and non-canonical roles of the histone methyltransferase EZH2 in mammary development and cancer. Mol Cell Endocrinol. 2013; 382(1):593-597. PMC: 3843995. DOI: 10.1016/j.mce.2013.05.002. View

15.

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

16.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

17.

Cho S, Kim Y, Sun H, Ahn H, Lee E, Yi K . Therapeutic potential of Dickkopf-1 in wild-type BRAF papillary thyroid cancer via regulation of β-catenin/E-cadherin signaling. J Clin Endocrinol Metab. 2014; 99(9):E1641-9. DOI: 10.1210/jc.2013-4467. View

18.

. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159(3):676-90. PMC: 4243044. DOI: 10.1016/j.cell.2014.09.050. View

19.

Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B . BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003; 95(8):625-7. DOI: 10.1093/jnci/95.8.625. View

20.

Mitselou A, Ioachim E, Peschos D, Charalabopoulos K, Michael M, Agnantis N . E-cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies. Exp Oncol. 2007; 29(1):54-60. View